EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Developing monoclonal antibody therapies for measles could lead to adverse pathogen evolution

David A Kennedy iD

PLOS Biology · 2026-03-03 · 24 (3) · e3003701

DOI: 10.1371/journal.pbio.3003701 ↗

At a glance

Journal article in PLOS Biology, published online on 2026-03-03. Written by David A Kennedy. Institution: Department of Biology and Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, Pennsylvania, United States of Am…. Major MEDLINE topics: Measles, Antibodies, Monoclonal, Measles virus. 10 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Monoclonal antibody therapies are being developed to treat measles in response to its recent resurgence. These therapies risk driving measles virus evolution in ways that might undermine the protection offered by vaccination, outweighing potential benefits.

Subjects

MeSH terms (MEDLINE)

MeaslesAntibodies, MonoclonalMeasles virusHumansMeasles VaccineAntibodies, ViralAnimals

Substances

Antibodies, MonoclonalMeasles VaccineAntibodies, Viral

Authors and institutions

  • Department of Biology and Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, Pennsylvania, United States of America.

ORCID profiles: David A Kennedy

Funding

  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Cite

APA

Kennedy, D. A. (2026). Developing monoclonal antibody therapies for measles could lead to adverse pathogen evolution. PLOS Biology, 24(3), e3003701. https://doi.org/10.1371/journal.pbio.3003701

Vancouver

Kennedy DA. Developing monoclonal antibody therapies for measles could lead to adverse pathogen evolution. PLOS Biology. 2026;24(3):e3003701. doi:10.1371/journal.pbio.3003701

BibTeX
@article{Kennedy2026,
  author = {Kennedy, David A},
  title = {Developing monoclonal antibody therapies for measles could lead to adverse pathogen evolution},
  journal = {PLOS Biology},
  year = {2026},
  volume = {24},
  number = {3},
  pages = {e3003701},
  doi = {10.1371/journal.pbio.3003701}
}
Start for free →